Anatomy Department and Stem Cell Unit, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Department of Chemistry, College of Science, University of Ha'il, Ha'il, Saudi Arabia.
Biosci Rep. 2022 Jun 30;42(6). doi: 10.1042/BSR20220465.
Colon cancer (CC) remains one of the leading causes of cancer death worldwide. Several mutations/polymorphisms have been implicated in CC development and/or progression. The role of the recently identified variants related to the long non-coding RNAs (lncRNAs) family has not yet been fully uncovered. In this sense, we aimed to explore the association between the lncRNA PUNISHER rs12318065 variant and the CC risk and/or prognosis.
A total of 408 CC (paired 204 cancer/non-cancer) tissues were genotyped using the TaqMan allelic discrimination assay.
"A" variant was associated with higher susceptibility to develop CC under heterozygote (A/C vs. C/C: OR = 1.39, 95%CI = 1.09-2.17, P=0.002), homozygote (A/A vs. C/C: OR = 2.63, 95%CI = 1.51-4.58, P=0.001), dominant (A/C-A/A vs. C/C: OR = 1.72, 95%CI = 1.15-02.57, P=0.008), and recessive (A/A vs. C/C-A/C: OR = 2.23, 95%CI = 1.34-3.72, P=0.001) models. Patients with metastasis were more likely to harbor A/A and A/C genotypes (16.7% and 14.1%) than 11% with the C/C genotype (P=0.027). Patients harboring C>A somatic mutation were more likely to develop relapse (52.6% vs. 26.5%, P=0.003), have poor survival (57.9% vs. 27.7%, P=0.001), and have shorter disease-free survival (43.2 ± 2.6 months vs. 56.8 ± 1.29 months, P<0.001) and overall survival (49.6 ± 2.4 months vs. 56.6 ± 0.99 months, P<0.001). Multivariate Cox regression analysis showed that patients with distal metastasis and C>A somatic mutation were three times more likely to die.
To our knowledge, the present study is the first to identify that the PUNISHER rs12318065 variant could be a novel putative driver of colon cancer and is associated with poor prognosis.
结肠癌(CC)仍然是全球癌症死亡的主要原因之一。有几种突变/多态性与 CC 的发展和/或进展有关。最近发现的与长非编码 RNA(lncRNA)家族相关的变异体的作用尚未完全揭示。在这种情况下,我们旨在探讨 lncRNA PUNISHER rs12318065 变体与 CC 风险和/或预后之间的关系。
使用 TaqMan 等位基因鉴别检测法对 408 例 CC(配对 204 例癌症/非癌症)组织进行基因分型。
“A”变体与杂合子(A/C 与 C/C:OR=1.39,95%CI=1.09-2.17,P=0.002)、纯合子(A/A 与 C/C:OR=2.63,95%CI=1.51-4.58,P=0.001)、显性(A/C-A/A 与 C/C:OR=1.72,95%CI=1.15-02.57,P=0.008)和隐性(A/A 与 C/C-A/C:OR=2.23,95%CI=1.34-3.72,P=0.001)模型中 CC 的易感性增加。有转移的患者更有可能携带 A/A 和 A/C 基因型(16.7%和 14.1%),而 C/C 基因型的患者为 11%(P=0.027)。携带 C>A 体细胞突变的患者更有可能复发(52.6%比 26.5%,P=0.003),生存状况较差(57.9%比 27.7%,P=0.001),无病生存期较短(43.2±2.6 个月比 56.8±1.29 个月,P<0.001)和总生存期(49.6±2.4 个月比 56.6±0.99 个月,P<0.001)。多变量 Cox 回归分析显示,远处转移和 C>A 体细胞突变的患者死亡风险增加三倍。
据我们所知,本研究首次发现 PUNISHER rs12318065 变体可能是结肠癌的一种新的潜在驱动因子,并与不良预后相关。